A
Ambagon Therapeutics
Biotech & Life Sciences · Eindhoven, Netherlands · Founded 2020
Biotechnology company developing small molecule drugs that target previously undruggable proteins for cancer treatment MoreLess
Ambagon Therapeutics is a biotechnology startup focused on expanding the druggable proteome by targeting intrinsically disordered proteins (IDPs), a class of proteins that have historically been considered undruggable. The company has developed a proprietary platform designed to create novel medicines capable of interacting with these challenging targets. By enabling therapeutic intervention at previously inaccessible sites within the proteome, Ambagon aims to address diseases that have eluded traditional drug discovery approaches. The company's scientific strategy centers on overcoming the limitations of conventional small molecule drugs, opening new avenues for treating complex conditions linked to IDPs.
Keywords: intrinsically disordered proteins, druggable proteome, undruggable targets, novel medicines, drug discovery, biotechnology, therapeutic platform, Ambagon Therapeutics
Company overview
Ambagon Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Eindhoven, Netherlands
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 67.3
Valuation & funding
Ambagon Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2025 | $5M | $425M | Undisclosed | ↗ |
| SERIES AOther financing | Jan 2022 | $85M | $340M | Abbvie Biotech Ventures · RA Capital Management · Droia Oncology Ventures · Inkef | ↗ |
| SEEDOther financing | Jul 2020 | $7.2M | $29M | RA Capital Management · Droia Oncology Ventures · MRL Ventures · Nextech Invest | ↗ |
| SPINOUTOther financing | Jul 2020 | $0 | — | Eindhoven University of Technology | ↗ |
Growth signals
Ambagon Therapeutics website traffic
Latest recorded traffic for Ambagon Therapeutics is 570 monthly website visits, down 43% over the last three months. Ambagon Therapeutics's team declined 5.9% over the past year.
Comparisons
Ambagon Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Ambagon Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Ambagon Therapeutics has talent and traffic
team presence
In the news
Latest news about Ambagon Therapeutics
Recent press, funding announcements, and product moves mentioning Ambagon Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Ambagon Therapeutics
An AI-synthesized read of the highest-engagement posts about Ambagon Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ambagon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.